SMi's 20th Annual Pain Therapeutics Conference 2020

SMi Group 11 - 12 May 2020, London, UK.
The 20th Annual Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals.

This year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.

Presentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors. Furthermore, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs.

Join SMi's leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.

Who should attend

Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:
  • Pain and Migraine
  • Inflammation
  • Chronic Pain
  • Neuropathic Pain
  • Analgesic pre-clinical development
  • Anaesthesia and Pain Management
  • CNS clinical trials
  • Ion Channel Pharmacology
  • Pharmacology Intelligence
  • Translational science
  • Drug development
  • Exploratory development

Early-bird rates

  • Book by 31st March and save £100

For further information and to register, please visit:
http://www.pain-therapeutics.co.uk/WPNwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...